Could N-acetylcysteine improve the safety of clozapine?

Human Psychopharmacology
Basile ChrétienCharles Dolladille

Abstract

Clozapine is an atypical antipsychotic indicated in patients with treatment-resistant schizophrenia which remains underused due to safety issues. Mechanisms behind these adverse effects are complex and not fully understood. They may involve immune-related mechanisms, direct toxic effects and oxidative stress. Clozapine-induced oxidative stress might indeed notably be involved in the onset of neutropenia, agranulocytosis, myocarditis, sialorrhea, and metabolic alterations. Therefore, the association of N-acetylcysteine (NAC), an easily accessible, low-cost and well tolerated antioxidant drug could be of interest in clozapine-treated patients to improve clozapine safety. Furthermore, according to recent studies NAC could help to improve schizophrenia symptoms. We believe that the use of NAC in the context of clozapine prescribing merits further study, as it could improve clozapine safety which may lead to a wider use and ultimately improve the healthcare of thousands of patients. NAC could also secondarily show positive knock-on effects for the patients by improving clinical symptoms of schizophrenia in synergy with clozapine, and by reducing substance abuse and thus by improving the patient's overall condition. However, given th...Continue Reading

References

Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lisa M GodselDavid M Engman
Sep 15, 2005·Journal of Clinical Psychopharmacology·Karin FehselAnsgar Klimke
Jul 3, 2007·Current Opinion in Pharmacology·Kondala R AtkuriLeonore A Herzenberg
May 10, 2008·The International Journal of Neuropsychopharmacology·Consuelo Walss-BassAsish R Chaudhuri
Dec 8, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Cedo MiljevicMihajlo B Spasic
Sep 21, 2010·Chemical Research in Toxicology·Sanja DragovicJan N M Commandeur
Dec 2, 2010·Journal of Psychiatry & Neuroscience : JPN·Olivia DeanMichael Berk
Dec 17, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Shelley L AmenDavid A Baker
Sep 5, 2014·Nature Communications·Jacqueline I GoldsteinPatrick F Sullivan
May 12, 2016·The Pharmacogenomics Journal·K van der WeideJ van der Weide
Nov 3, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Dan SiskindSteve Kisely
Nov 7, 2018·The Mental Health Clinician·Bryan K SackeyCynthia A Gutierrez
Nov 26, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yuya MizunoOliver D Howes
Dec 13, 2019·The Australian and New Zealand Journal of Psychiatry·Caitlin Ob YollandDan Siskind
Feb 19, 2020·Translational Psychiatry·Paul LacazeMunir Pirmohamed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Lancet. Psychiatry
Evanthia Achilla, Paul McCrone
The British Journal of Psychiatry : the Journal of Mental Science
R W KerwinM Launer
Medicina clínica
D Montero, F J de Abajo
Neurología : publicación oficial de la Sociedad Española de Neurología
G Linazasoro
© 2021 Meta ULC. All rights reserved